GlassScriptPhysician profile
Philip L Chatham
NPI 1740279264
$4,345.36
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $251 · 2021: $1,134 · 2022: $1,261 · 2023: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379 · Long Term Medical Supply Or Device Loan: $299 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.09 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $810.65 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $354.60 | 2019-2023 | Opdivo |
| Eisai INC. | $324.50 | 2019-2023 | |
| Amgen INC. | $242.50 | 2019-2023 | Lumakras |
| Incyte Corporation | $214.26 | 2021-2023 | Jakafi |
| Janssen Biotech, INC. | $179.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $145.98 | 2019-2023 | Tagrisso |
| Pfizer INC. | $125.22 | 2019-2021 | |
| Seagen INC. | $116.26 | 2019-2023 | Padcev |
| Medtronic USA, INC. | $112.53 | 2019 | |
| Puma Biotechnology, INC. | $106.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $100.54 | 2019-2022 | |
| Glaxosmithkline, LLC. | $92.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.02 | 2019-2022 | |
| Myovant Sciences INC. | $84.80 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Chatham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.